Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis

Journal of Neurology

Volumn 252, Issue 8, 2005, Pages 908-915

  Matsui, M ^a   Araya, Shin Ichi ^a   Wang, Hui Yun ^a   Matsushima, K ^b   Saida, Takahiko ^a  

^a UTANO NATIONAL HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

CD4 +CXCR3+ cell; CD4+CD25+ cell; Cerebrospinal fluid; Inflammation; Multiple sclerosis

Indexed keywords

ALBUMIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 4; INTERLEUKIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; BLOOD LEVEL; BLOOD SAMPLING; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION;

ANTIGENS, CD; CENTRAL NERVOUS SYSTEM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, CELLULAR; INTERLEUKINS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; STATISTICS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTE SUBSETS;

EID: 23944448666     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0778-z     Document Type: Article

References (35)

1. Calder V, Owen S, Watson C, Feldmann M, Davison A (1989) MS: a localized immune disease of the central nervous system. Immunol Today 10:99-103
2. Calopa M, Bas J, Mestre M, Arbizu T, Peres J, Buendia E (1995) T cell subsets in multiple sclerosis: a serial study. Acta Neurol Scand 92:361-368
3. + memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diag Lab Immunol 2:249-252
4. Danilov AI, Andersson M, Bavand N, Wiklund NP, Olsson T, Brundin L (2003) Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmunol 136:112-118
5. Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, van Lier RAW, Barkhof F, Uitdehaag BMJ, Polman CH (2002) Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis. J Neuroimmunol 133:225-232
6. Eoli M, Ferrarini M, Dufour A, Heltaj S, Bevilacqua L, Comi G, Cosi V, Filippini G, Martinelli V, Milanese C, La Mantia L, Salmaggi A (1993) Presence of T-cell subset abnormalities in newly diagnosed cases of multiple sclerosis and relationship with short-term clinical activity. J Neurol 240:79-82
7. Fassbender K, Ragoschke A, Rossol S, Schwartz A, Mielke O, Pauling A, Hennerici M (1998) Increased release of interleukin-12p40 in MS. Association with intracerebral inflammation. Neurology 51:753-758
8. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V (2001) Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 115:192-198
9. Hafler DA, Weiner HL (1989) MS: a CNS and systemic autoimmune disease. Immunol Today 10:104-107
10. Hemler ME, Brenner MB, McLean JM, Strominger JL (1984) Antigenic stimulation regulates the level of expression of interleukin 2 receptor on human T cells. Proc Natl Acad Sci USA 81:2172-2175
11. + T cells in multiple sclerosis. J Immunol 162:1811-1817
12. Karp CL (1999) Interleukin-12: amiss in MS. Ann Neurol 45:689-692
13. Khoury SJ, Guttmann CRG, Orav EJ, Kikinis R, Jolesz FA, Weiner HL (2000) Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol 57:1183-1189
14. Kieseier BC, Seifert T, Giovannoni G, Hartung H-P (1999) Matrix metalloproteinases in inflammatory demyelination. Targets for treatment. Neurology 53:20-25
15. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, Wu L, Butcher EC (2001) Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 108:1331-1339
16. Kivisäkk P, Trebst C, Liu Z, Tucky BH, Sørensen TL, Rudick RA, Mack M, Ransohoff RM (2002) T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin Exp Immunol 129:510-518
17. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S, Miller KM, Hauser SL, Kappos L (1998) Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121:2327-2334
18. Mahad DJ, Howell SJL, Woodroofe MN (2002) Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 72:498-502
19. Matsui M, Araya S, Wang H-Y, Onai N, Matsushima K, Saida T (2003) Circulating lymphocyte subsets linked to intracellular cytokine profiles in normal humans. Clin Exp Immunol 134:225-231
20. McDonald WI, Compston A, Edan G, Goodkin D, Hartung H-S, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
21. Misu T, Onodera H, Fujihara K, Matsushima K, Yoshie O, Okita N, Takase S, Itoyama Y (2001) Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J Neuroimmunol 114:207-212
22. Morimoto C, Rudd CE, Letvin NL, Schlossman SF (1987) A novel epitope of the LFA-1 antigen which can distinguish killer effector and suppressor cells in human CD8 cells. Nature 330:479-482
23. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N EngL J Med 343:938-952
24. Olsson T (1995) Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 144:245-268
25. + lymphocytes in multiple sclerosis. J Neurol 239:437-440
26. Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101:455-458
27. Salonen R, Ilonen J, Jägerroos H, Syrjälä H, Nurmi T, Reunanen M (1989) Lymphocyte subsets in the cerebrospinal fluid in active multiple sclerosis. Ann Neurol 25:500-502
28. Sørensen PS (1999) Biological markers in body fluids for activity and progression in multiple sclerosis. Mult Scler 5:287-290
29. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM (1999) Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103:807-815
30. Sørensen TL, Sellebjerg F, Jensen CV, Strieter RM, Ransohoff RM (2001) Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol 8:665-672
31. Tourtellotte WW, Staugaitis SM, Walsh MJ, Shapshak P, Baumhefner RW, Potvin AR, Syndulko K (1985) The basis of intra-blood-brain-barrier IgG synthesis. Ann Neurol 17:21-27
32. Trebst C, Ransohoff RM (2001) Investigating chemokines and chemokine receptors in patients with multiple sclerosis. Opportunities and challenges. Ann Neurol 58:1975-1980
33. van Boxel-Dezaire AHH, Hoff SCJ, van Oosten BW, Verweij CL, Dräger AM, Adèr HJ, van Houwelingen JC, Barkhof F, Polman CH, Nagelkerken L (1999) Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Arch Neurol 45:695-703
34. Wang H-Y, Matsui M, Araya S-i, Onai N, Matsushima K, Saida T (2002) Chemokine receptors associated with immunity within and outside the central nervous system in early relapsing-remitting multiple sclerosis. J Neuroimmunol 133:184-192
35. Wang H-Y, Matsui M, Saida T (2002) Immunological disturbances in the central nervous system linked to MRI findings in multiple sclerosis. J Neuroimmunol 125:149-154